Recurrent Rathke's Cleft Cysts: Incidence and Surgical Management in a Tertiary Pituitary Center over 2 Decades. Issue 6 (22nd September 2018)

• Record Type: Journal Article
• Authors: Wedemeyer, Michelle A; Lin, Michelle; Fredrickson, Vance L; Arakelyan, Anush; Bradley, Daniel; Donoho, Daniel A; Hurth, Kyle M; Weiss, Martin H; Carmichael, John D; Zada, Gabriel
• Is Part Of: Operative neurosurgery. Volume 16:Issue 6(2019)
• Page Start: 675
• Page End: 684
• Publication Date: 2018-09-22
• Subjects: Complications -- Endoscopic endonasal approach -- Microsurgery -- Rathke's cleft cyst -- Recurrence -- Transsphenoidal; Nervous system -- Surgery -- Periodicals; 617.480590
• DOI: 10.1093/ons/opy258
• Languages: English
• ISSNs: 2332-4252

Abstract

Abstract: Background: Limited data exist pertaining to outcomes following surgery for recurrent Rathke's cleft cysts (RCC). Objective: To determine treatment outcomes in patients undergoing reoperation for recurrent or residual RCCs. Methods: A retrospective analysis of 112 consecutive RCC operations in 109 patients between 1995 and 2017 was conducted. Results: Eighteen patients underwent 21 RCC reoperations with a mean follow-up of 58 mo. Patient symptoms prior to reoperation included headaches (14, 66.7%) and vision loss (12, 57.1%). Thirteen of 18 patients (72.2%) required hormone supplementation prior to reoperation including 5 with diabetes insipidus (DI). Mean RCC diameter was 16 mm and 76% had suprasellar extension. Compared to index RCC cases, intraoperative cerebrospinal fluid leak repair was more common in reoperation cases (15/21, 71% vs 43/91, 47%, P = .05). There was 1 carotid artery injury without neurological sequelae, and 2 postoperative cerebrospinal fluid (CSF) leaks (9.5%). Rates of transient hyponatremia (3/10, 30% vs 4/91, 4.4%, P = .04) and transient DI (5/10, 50% vs 17/91, 18.7%, P = .04) were higher in the reoperation vs index group. Improved headaches and vision were reported in 4/12 (33%) and 8/12 (61.5%) of RCC reoperation patients, respectively. Two patients developed new permanent DI. A higher proportion of reoperation patients had RCC squamous metaplasia (24% vs 5.4%, P = .02) or wall inflammation (42.9% vs 2.2%, P < .001) on pathological examination. CONCLUSION: Reoperation for RCCs is generally safe at tertiary pituitary centers and often results in improved vision. Hypopituitarism is less likely to improve following reoperation for recurrent RCCs. Several histopathological features may help characterize "atypical RCCs" with a higher likelihood of recurrence/progression.